CONMED Corp CNMD
CONMED Corp (CNMD) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 2.29% (safety: moderate). FY2025 revenue was $1.4B at a 3.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.7 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.154 |
| Retained earnings / assets | 0.253 |
| EBIT / assets | 0.044 |
| Equity / liabilities | 0.799 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CNMD | CONMED Corp | 5/9 | 2.97 | 23 | +5.2% |
| LIVN | LivaNova PLC | 4/9 | 0.72 | — | +10.7% |
| MASI | MASIMO CORP | 7/9 | 6.71 | — | +9.4% |
| ITGR | Integer Holdings Corp | 6/9 | 3.52 | 31 | +8% |
| TMDX | TransMedics Group, Inc. | 6/9 | 4.04 | 12.4 | +37.1% |
| AXGN | Axogen, Inc. | 5/9 | -0.43 | — | +20.2% |
| OM | Outset Medical, Inc. | 6/9 | -9.87 | — | +5.1% |
About CONMED Corp
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors, used in minimally invasive surgeries; and electrosurgical solution comprise monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products to treat diseases of dilation, hemostasis, biliary, stricture management, infection prevention, and patient monitoring include ECG electrodes, EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.
FAQ
Is CNMD financially healthy?
CONMED Corp's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does CNMD pay a dividend, and is it safe?
Yes. CONMED Corp pays a dividend yielding about 2.29% with a 52.6% payout ratio, rated “moderate” for safety.
How profitable is CNMD?
In FY2025, CONMED Corp had a net margin of 3.4% and a return on equity of 4.6%.
Is CNMD overvalued or undervalued?
CONMED Corp trades at about 32.8× trailing earnings — below its 10-year norm (10-year range 16.9×–349.7×, median 49.9×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for CNMD?
The average Wall-Street price target for CONMED Corp is $39.60, about 20.0% below the recent price, from 5 analysts (consensus: hold).
Is CNMD a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on CONMED Corp: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 23.0×, a dividend yield of 2.29%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.